Chemotherapy increases caspase-cleaved cytokeratin 18 in the serum of breast cancer patients

Benson JR, Jatoi I, Keisch M, Esteva FJ, Makris A, Jordan VC. Early breast cancer. Lancet 2009; 373: 1463-79.10.1016/S0140-6736(09)60316-0Search in Google Scholar

Plesnicar A, Golicnik M, Fazarinc IK, Kralj B, Kovac V, Plesnicar BK. Attitudes of midwifery students towards teaching breast-self examination. Radiol Oncol 2010; 44: 52-6.10.2478/v10019-010-0009-9Search in Google Scholar

Ovcaricek T. Frkovic SG, Matos E, Mozina B, Borstnar S. Triple negative breast cancer - prognostic factors and survival. Radiol Oncol 2011; 45: 46-52.10.2478/v10019-010-0054-4Search in Google Scholar

Strojan P. Cysteine cathepsins and stefins in head and neck cancer: an update of clinical studies. Radiol Oncol 2008; 42: 69-81.10.2478/v10019-008-0006-4Search in Google Scholar

Hickman JA, Beere HM, Wood AC, Waters CM, Parmar R. Mechanisms of cytotoxicity caused by antitumour drugs. Toxicol Lett 1992; 64: 553-61.10.1016/0378-4274(92)90231-8Search in Google Scholar

Ohmori T, Podack ER, Nishio K, Takahashi M, Miyahara Y, Takeda Y, et al. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem Biophys Res Commun 1993; 192: 30-6.10.1006/bbrc.1993.1377Search in Google Scholar

Walton MI, Whysong D, O'Connor PM, Hockenbery D, Korsmeyer SJ, Kohn KW. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res 1993; 53: 1853-61.Search in Google Scholar

Hagg M, Bivén K, Ueno T, Rydlander L, Björklund P, Wiman KG, et al. A novel high-through-put assay for screening of pro-apoptotic drugs. Invest New Drugs 2002; 20: 253-9.10.1023/A:1016249728664Search in Google Scholar

Linder S. Cytokeratin markers come of age. Tumour Biol 2007; 28: 189-95.10.1159/000107582Search in Google Scholar

Ueno T, Toi M, Linder S. Detection of epithelial cell death in the body by cytokeratin 18 measurement. Biomed Pharmacother 2005; 59 (Suppl): S359-62.10.1016/S0753-3322(05)80078-2Search in Google Scholar

Leers MP, Kölgen W, Björklund V, Bergman T, Tribbick G, Persson B, et al. Immunocytochemical detection and mapping of a cytokeratin 18 neoepitope exposed during early apoptosis. J Pathol 1999; 187: 567-72.10.1002/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-JSearch in Google Scholar

Zhang L, Kavanagh BD, Thorburn AM, Camidge DR. Preclinical and clinical estimates of the basal apoptotic rate of a cancer predict the amount of apoptosis induced by subsequent proapoptotic stimuli. Clin Cancer Res 2010; 16: 4478-89.10.1158/1078-0432.CCR-10-085920630997Search in Google Scholar

Linder S, Olofsson MH, Herrmann R, Ulukaya E. Utilization of cytokeratin-based biomarkers for pharmacodynamic studies. Expert Rev Mol Diagn 2010; 10: 353-9.10.1586/erm.10.1420370591Search in Google Scholar

Holdenrieder S, Stieber P. Circulating apoptotic markers in the management of non-small cell lung cancer. Cancer Biomarkers 2010; 6: 197-210.10.3233/CBM-2009-013020660965Search in Google Scholar

Brandt D, Volkmann X, Anstätt M, Länger F, Manns MP, Schulze-Osthoff K, et al. Serum biomarkers of cell death for monitoring therapy response of gastrointestinal carcinomas. Eur J Cancer 2010; 46: 1464-73.10.1016/j.ejca.2010.01.03720202824Search in Google Scholar

de Haas EC, di Pietro A, Simpson KL, Meijer C, Suurmeijer AJ, Lancashire LJ, et al. Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. Neoplasia 2008; 10: 1041-8.10.1593/neo.08620254659018813353Search in Google Scholar

Wu YX, Wang JH, Wang H, Yang XY. Study on expression of Ki-67, early apoptotic protein M30 in endometrial carcinoma and their correlation with prognosis. Zhonghua Bing Li Xue Za Zhi 2003; 32: 314-8.Search in Google Scholar

Yaman E, Coskun U, Sancak B, Buyukberber S, Ozturk B, Benekli M. Serum M30 levels are associated with survival in advanced gastric carcinoma patients. Int Immunopharmacol 2010; 10: 719-22.10.1016/j.intimp.2010.03.01320362077Search in Google Scholar

Beachy SH, Repasky EA. Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update. Cancer Immunol Immunother 2008; 57: 759-75.10.1007/s00262-007-0445-618188561Search in Google Scholar

Kramer G, Erdal H, Mertens HJ, Nap M, Mauermann J, Steiner G, et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 2004; 64: 1751-6.10.1158/0008-5472.CAN-03-2455Search in Google Scholar

Demiray M, Ulukaya EE, Arslan M, Gokgoz S, Saraydaroglu O, Ercan I, et al. Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study. Cancer Invest 2006; 24: 669-76.10.1080/0735790060098130717118776Search in Google Scholar

Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-85.10.1200/JCO.1998.16.8.26729704717Search in Google Scholar

Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998; 16: 93-100.10.1200/JCO.1998.16.1.93Search in Google Scholar

Scholl SM, Beuzeboc P, Harris AL, Pierga JY, Asselain B, Palangié T, et al. Is primary chemotherapy useful for all patients with primary invasive breast cancer? Recent results. Cancer Res 1998; 152: 217-26.Search in Google Scholar

Holdenrieder S, Stieber P. Apoptotic markers in cancer. Clin Biochem 2004; 37: 605-617.10.1016/j.clinbiochem.2004.05.003Search in Google Scholar

Degterev A, Yuan J. Expansion and evolution of cell death programmes. Nat Rev Mol Cell Biol 2008; 9: 378-90.10.1038/nrm2393Search in Google Scholar

Ozturk B, Coskun U, Sancak B, Yaman E, Buyukberber S, Benekli M. Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors. Int Immunopharmacol 2009; 9: 645-8.10.1016/j.intimp.2009.02.004Search in Google Scholar

Ueno T, Toi M, Bivén K, Bando H, Ogawa T, Linder S. Measurement of an apoptotic product in the sera of breast cancer patients. Eur J Cancer 2003; 39: 769-74.10.1016/S0959-8049(02)00865-1Search in Google Scholar

Olofsson MH, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H, et al. Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res 2007; 13: 3198-206.10.1158/1078-0432.CCR-07-0009Search in Google Scholar

Ulukaya E, Yilmaztepe A, Akgoz S, Linder S, Karadag M. The levels of caspase cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer 2007; 56: 399-404.10.1016/j.lungcan.2007.01.015Search in Google Scholar

Meyn RE, Stephens LC, Hunter NR, Milas L. Apoptosis in murine tumors treated with chemotherapy agents. Anticancer Drugs 1995; 6: 443-50.10.1097/00001813-199506000-00013Search in Google Scholar

Ellis PA, Smith IE, McCarthy K, Detre S, Salter J, Dowsett M. Preoperative chemotherapy induces apoptosis in early breast cancer. Lancet 1997; 349: 849.10.1016/S0140-6736(05)61752-7Search in Google Scholar

Green AM, Steinmetz ND. Monitoring apoptosis in real time. Cancer J 2002; 8: 82-92.10.1097/00130404-200203000-0000211999952Search in Google Scholar